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Abstract
We analyzed the activation and function of dendritic cells (DCs)
in the spleens of diseased, lupus-prone NZM2410 and NZB-W/
F1 mice and age-matched BALB/c and C57BL/6 control mice.
Lupus DCs showed an altered ex vivo costimulatory profile, with
a significant increase in the expression of CD40, decreased
expression of CD80 and CD54, and normal expression of
CD86. DCs from young lupus-prone NZM2410 mice, before the
development of the disease, expressed normal levels of CD80
and CD86 but already overexpressed CD40. The increase in
CD40-positive cells was specific for DCs and involved the
subset of myeloid and CD8α+ DCs before disease onset, with a
small involvement of plasmacytoid DCs in diseased mice. In
vitro data from bone marrow-derived DCs and splenic myeloid
DCs suggest that the overexpression of CD40 is not due to a
primary alteration of CD40 regulation in DCs but rather to an
extrinsic stimulus. Our analyses suggest that the defect of
CD80 in NZM2410 and NZB-W/F1 mice, which closely
resembles the costimulatory defect found in DCs from humans
with systemic lupus erythematosus, is linked to the autoimmune
disease. The increase in CD40 may instead participate in
disease pathogenesis, being present months before any sign of
autoimmunity, and its downregulation should be explored as an
alternative to treatment with anti-CD40 ligand in lupus.
Introduction
Dendritic cells (DCs) initiate and maintain immune responses,
and evidence suggests that they have an active role in the
pathogenesis of lupus: human DCs progressively disappear
from the blood of patients with lupus [1], possibly because
they are sequestered in the secondary lymphoid organs; they
show an abnormal costimulatory profile [2], with a specific
defect of expression of CD80 [3,4]; and sera from patients
with lupus have been shown to induce differentiation of periph-
eral blood mononuclear cells into DCs, with a mechanism
dependent on type I IFN-α [5], a cytokine produced in large
amounts by plasmacytoid DCs (pDCs) [6]. DCs accumulate
both in T cell areas [7] and B cell areas [8] in the lymph nodes
and spleens of lupus-prone MRL/lpr (Fas-deficient) and NZB-
W/F1 mice; in the latter strain, the accumulation has been
attributed to high levels of Flt-3L [9], which is also increased
in patients with lupus [10]. In (SWR × NZB) F1 mice, DC accu-
mulation was inhibited by long-term treatment with anti-CD40
ligand (anti-CD40L), suggesting that it might be dependent on
CD40-CD40L interaction [11]. Finally, injection of syngeneic
DCs accelerates the onset of the disease [12]. The antigen-
presenting capability of DCs in lupus-prone mice requires fur-
ther characterization, because normal [9], defective [13], and
excessive [14] antigen-presenting cell functions have all been
reported in different murine models of lupus.
Although many studies have focused on the relevance of DCs
in lupus-prone mice [9,11,15], the costimulatory phenotype of
DCs ex vivo has not been thoroughly investigated, especially
without the limitations of isolation in vitro. A recent report
describes the phenotype of DCs in C57BL/6.Sle3 mice, a
congenic strain of mice in which one of the NZM2410-derived
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lupus susceptibility loci, Sle3, was introgressed onto the nor-
mal C57BL/6 (B6) background [14]. These mice have low lev-
els of autoantibodies and lymphocyte alterations but do not
develop overt lupus disease with the characteristic lupus
nephritis. DCs from B6.Sle3 mice showed higher levels of
expression of costimulatory molecules, elevated production of
cytokines, and increased T cell stimulatory capacity before and
after the onset of the disease [14].
In our study we analyzed DCs in the original NZM2410 and
NZB-W/F1 mice before and after the onset of overt disease
and found different results from those reported in B6.Sle3
mice. We used a protocol that maximizes DC yield [16] to ana-
lyze the characteristics of the three major DC subsets, namely
myeloid, CD8α+, and plasmacytoid; and to compare lupus-
prone mice with multiple age-matched non-autoimmune mice.
We show here that DCs from diseased NZM2410 lupus-
prone mice have an altered costimulation pattern, with an
abnormal ratio of CD80 to CD86 due to decreased levels of
CD80 and normal levels of CD86. Additionally, we detected
decreased levels of CD54, and a specific increase in CD40 on
lupus DCs. Whereas the alteration in CD80/CD86 ratio is evi-
dent only after the onset of the disease, the overexpression of
CD40 precedes the onset of lupus and is sustained even dur-
ing the course of the disease. We therefore propose that the
decreased ratio of CD80 to CD86 in lupus DCs may be linked
to the full development of the autoimmune disease, whereas
the overexpression of CD40 may be important in the patho-
genesis of this autoimmune disease.
Materials and methods
Mice
NZM2410 (Taconic and Jackson Laboratories), NZB-ZW/F1J,
BALB/c, and C57BL/6J (Jackson Laboratories) mice were
bred and maintained in accordance with the guidelines of the
IACUC and all the experimental procedures were approved by
the IACUC of the Children's Hospital of Philadelphia, an AAA-
LAC accredited facility.
Immunostaining for flow cytometry ex vivo
To study DCs in the spleen ex vivo, we used a modified proto-
col from Vremec and colleagues [16]. In brief, we injected
excised spleens with a solution of 0.8 mg/ml collagenase and
0.1 mg/ml DNAse, then teased the tissue into small pieces,
and incubated it for 30 minutes at 37°C. From this point
onward, all procedures were performed on ice to minimize the
spontaneous activation of DCs in vitro. We pushed spleen
fragments through a cell strainer (100 µm) and inhibited colla-
genase with 5 mM EDTA; then we lysed the red blood cells
with Hybrimax (Sigma, St Louis, MO, USA) and counted the
cells. We prestained the total population of splenocytes for 10
minutes with rat anti-mouse CD16/CD32 (clone 2.4G2) anti-
bodies to block FcγR, and then stained for 30 minutes with the
following monoclonal antibodies from BD Bioscience
Pharmingen (San Diego, CA, USA): Allophycocyanin -conju-
gated hamster anti-mouse CD11c (to recognize DCs) and
PerCP-Cy5.5-rat anti-mouse CD19 (to gate out CD11clow B
cells). In some experiments, biotinylated anti-F4/80 and NK1.1
monoclonal antibodies, followed by Streptavidin PerCP-Cy5.5
were used to gate out CD11clow macrophages and natural
killer cells, respectively. We found that these cells do not con-
tribute significantly to the CD11c+ population.
We studied DC costimulatory molecules with phycoerythrin-
conjugated rat anti-mouse CD80, CD86, and CD54 and with
fluorescein isothiocyanate-conjugated hamster anti-mouse
CD40. To study CD40 expression in DC subsets, we used
phycoerythrin-conjugated rat anti-mouse CD8α, CD11b, and
B220. In parallel tubes we stained cells with isotype control
antibodies to determine non-specific staining. After staining,
cells were washed in phosphate-buffered saline, fixed in 1%
formaldehyde, and analyzed on a FACSCalibur flow cytometer
(BD Biosciences Pharmingen, San Diego, CA, USA). We col-
lected a large number of cells per sample (5 × 105 cells per
tube), allowing us to study small populations among the splen-
ocytes, such as the CD11c+ DCs (about 2 to 4% of the splen-
ocytes) and the smaller subsets: the myeloid DCs (recognized
as CD11c+ CD11b+ cells), the pDCs and the CD8α+ DCs
(recognized as CD11c+ B220+ cells and CD11c+ CD8α+
cells, respectively). The large number of cells yielded a suffi-
ciently large number of events (more than 2,000 for subsets,
and up to 18,000 for the all DC populations) to guarantee reli-
able results.
Bone marrow-derived DCs
We generated bone marrow-derived DCs (BM-DCs) as
described previously [17]. In brief, we eliminated T cell and B
cell contaminants from bone marrow with anti-Thy 1.2 and
anti-B220 magnetic beads and MACS columns (Miltenyi Bio-
tech, Bergisch Gladbach, Germany); then seeded bone mar-
row precursors in 24-well plates at 106 cells/ml in 10% fetal
bovine serum in complete IMDM (Iscove's modified Dul-
becco's medium) containing glutamine, 2-mercaptoethanol,
and antibiotics, and enriched with 3 ng/ml granulocyte/macro-
phage colony-stimulating factor (GM-CSF) and 2.5 ng/ml
interleukin-4 (BD Bioscience Pharmingen, San Diego, CA,
USA). We used BM-DCs at day 6 to 7 of culture.
Isolation of splenic myeloid DCs
We isolated splenic myeloid DCs as described previously
[18]. In brief, we freed the DCs from the extracellular matrix, as
described above. We plated the splenocytes on polystyrene
Petri dishes to let DCs and macrophages adhere, and washed
out the non-adherent cells after 90 minutes. We then incu-
bated the adherent cells overnight in complete medium
enriched with 10 ng/ml GM-CSF. On the following day, we
collected the floating DCs while leaving the strongly adherent
macrophages on the plastic. After harvesting, we stained the
isolated splenic DCs as described above.Available online http://arthritis-research.com/content/8/2/R49
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Statistical analyses
We analyzed the results with the non-parametric Kruskal-Wal-
lis test and the non-parametric post hoc Mann-Whitney test to
evaluate the differences between experimental groups. We
considered p < 0.05 to be significant.
Results
DCs from lupus-prone mice accumulate with age
We studied DCs in spleens of lupus-prone NZM2410 mice in
comparison with non-autoimmune age-matched BALB/c and
B6 mice. NZM2410 mice, derived by selective inbreeding of
the progeny of NZB-W/F1 mice, resemble, both serologically
and clinically, the manifestations of human systemic lupus ery-
thematosus (SLE) [19]. Because the parental NZB and NZW
mice display some autoimmune features, we chose as controls
two non-autoimmune strains of mice, B6 and BALB/c, which
in the literature are the most commonly used for comparison
with NZM2410 [20,21] and NZB-W/F1 mice [12,22], respec-
tively. Differences shared by these two non-autoimmune mice
in comparison with the NZM2410 mice are likely to be lupus
specific. We first studied mice with lupus at 6 to 9 months of
age (adult mice). The prevalence of the autoimmune disease is
about 90% at this age. For our experiments, we selected mice
that showed high titers of anti-DNA antibodies in their sera,
detected with a specific ELISA (not shown). Additionally, we
assessed kidney damage by detecting elevated proteinuria
(more than 300 mg/dl) and blood urea nitrogen (more than 26
mg/dl), and an increase in body weight (45 to 50 g) due to
fluid retention from kidney failure (not shown). Age-matched
BALB/c and B6 mice did not have anti-DNA antibodies and
displayed levels of proteinuria in the normal range for mice (30
to 100 mg/dl), normal blood urea nitrogen (less than 26 mg/
dl), and stable adult body weight (25 to 30 g) (not shown).
We also investigated DCs from spleens of mice 6 to 8 weeks
old (young). At this age, no sign of autoimmunity (anti-DNA
antibodies or kidney damage) is evident in the NZM2410 or in
the NZB-W/F1 model of lupus.
To study DCs ex vivo we performed no cell selection, to avoid
any loss of DC subsets. We therefore stained the entire pop-
ulation of splenocytes and analyzed a large number of cells by
flow cytometry (see details in Methods). Figure 1a shows the
gate used to analyze DCs. We found that, after the onset of
disease, splenic DCs accumulate with age (Figure 1b,c).
Indeed, we found significant differences in percentages and
absolute numbers of DCs between young and adult
NZM2410 mice. Such accumulation with age is not present in
either BALB/c or B6 mice: in these strains, DC percentages
and absolute numbers were not significantly different in young
and adult mice (Figure 1b,c). These data are consistent with
the significant difference in CD11c+ DC numbers between
lupus-prone and BALB/c adult mice reported in NZW-BXSB/
F1 [9] and in NZB-W/F1 mice (LC, JD, DKS, LF, RC, SG,
Figure 1
DCs accumulate with age in mice with lupus DCs accumulate with age in mice with lupus. (a) To study DCs, we analyzed the total population of splenocytes in mice 6 to 8 weeks old (young) 
and in mice 6 to 9 months old (old) and gated for CD11c+ cells that were negative for the B cell marker CD19. (b,c) Percentages (b) and absolute 
numbers (c) of DCs gated as in (a). Each circle represents the percentage or absolute number of CD11c+ cells in one individual mouse, and the hor-
izontal bars represent the average of each group. Results of the Mann-Whitney test analyses are shown. N.S. indicates p > 0.05.Arthritis Research & Therapy    Vol 8 No 2    Colonna et al.
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Figure 2
DCs express an altered costimulatory phenotype in lupus diseased mice DCs express an altered costimulatory phenotype in lupus diseased mice. (a) To study DCs, we analyzed the total population of splenocytes in mice 
6 to 9 months old and gated for CD11c+ cells that were negative for the B-cell marker CD19. (b) DCs from mice with lupus (thick dark histograms) 
express lower levels of CD80, normal levels of CD86, and higher levels of CD40 than DCs of non-autoimmune mice (grey filled histograms). The 
highlighted numbers are the percentages of DCs positive for the indicated markers and are representative of several mice analyzed and shown in (c-
e). The vertical line delineates the threshold of positivity, set on the isotype control background less than 1% (dotted histograms). (c-e) Positivity for 
CD80 (c), CD86 (d), and CD40 (e) in DCs gated as in (a). Each circle represents the percentage of positive cells in one individual mouse, and the 
horizontal bars represent the average of each group. (f,g) Averages and standard deviations of CD40 mean fluorescence intensity for expression in 
DCs from mice 6 to 9 months old of the indicated strains. We analyzed four to nine mice per group in (f) and seven to nine mice per group in (g). 
Results of the Kruskal-Wallis test analyses are shown in the graphs (k-w) and the post hoc Mann-Whitney test analyses are shown below the graphs. 
N.S. indicates p > 0.05.Available online http://arthritis-research.com/content/8/2/R49
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unpublished data). In addition, we propose the new concept
that the distribution of DCs is a variable among different
strains (compare B6 with BALB/c) and that DC accumulation
needs to be measured by comparing different ages in a single
strain. These observations suggest that DC accumulation is
common to at least three murine models of lupus [8,9,11] and
therefore that it is likely to be important in lupus development.
DCs from lupus mice express an altered ratio of CD80 to 
CD86 ex vivo
The analysis of the costimulatory molecules expressed by DCs
ex vivo (Figure 2a,b) showed that NZM2410 mice 6 to 9
months old (adult) had a lower percentage of DCs expressing
CD80, whereas the positivity for CD86 was similar to that of
the non-autoimmune mice (Figure 2c–e). Moreover, the com-
parable levels of CD80 and CD86 in BALB/c and B6 DCs
confirmed the feasibility of using these two strains of mice for
comparison with the lupus-prone strain. As was expected, we
found a similar profile (normal CD86 and low CD80) in age-
matched NZB-W/F1 mice (not shown). Furthermore, in both
NZM2410 and NZB-W/F1 mice, we found a decreased
expression of the adhesion molecule CD54 on lupus DCs in
comparison with non-autoimmune age-matched BALB/c DCs
(Figure 2b and not shown).
A defect in the expression of the costimulatory molecule CD80
and the adhesion molecule CD54, in the presence of normal
levels of the costimulatory molecule CD86, suggests a patho-
logic state of activation of DCs arising during the disease.
Increase in CD40-positive DCs in diseased mice ex vivo
We also found that CD40 expression was highly significantly
upregulated in DCs from spleens of diseased NZM2410 mice
in comparison with age-matched non-autoimmune mice (Fig-
ure 2b,e). The increase in the percentage of CD40-positive
DCs was accompanied by an increase in CD40 mean fluores-
cence intensity (MFI) (Figure 2f). The levels of CD40 positivity
in DCs of the two non-autoimmune strains were significantly
different, but they were both much lower than in lupus DCs
(Figure 2e,f). We found the same constitutive overexpression
of CD40 in NZB-W/F1 DCs (Figure 2g). The increase in
CD40 MFI was not accompanied by an increase in the maxi-
mal levels of CD40 expression (Figure 2b). These data sug-
gest an increased number of activated DCs rather than an
increased capacity of lupus DCs to express CD40 once acti-
vated.
The altered CD80/CD86 ratio does not precede the onset 
of lupus disease
We asked whether alterations of the activation markers in
lupus DCs were secondary to the inflammatory process that
characterizes the autoimmune disease, or whether they were
instead primary events and possibly involved in lupus patho-
genesis. We therefore investigated the costimulatory pheno-
type of DCs from spleens of mice 6 to 8 weeks old (young). At
this age, no sign of autoimmunity (anti-DNA antibodies or kid-
ney damage) is evident in the NZM2410 or in the NZB-W/F1
model of lupus. We found that DCs from lupus-prone mice
expressed levels of CD80 and CD86 comparable to those
Figure 3
Increase in CD40-positive DCs pre-dates lupus onset of disease, whereas CD80/CD86 balance is normal Increase in CD40-positive DCs pre-dates lupus onset of disease, whereas CD80/CD86 balance is normal. Percentages of cells positive for CD80 
(a), CD86 (b), and CD40 (c) in DCs from spleens of young (6 to 8 weeks old) mice. We analyzed DCs as described in Figure 2. Results of the 
Kruskal-Wallis test analyses are shown in the graphs (k-w) and the post hoc Mann-Whitney test analyses are shown below the graphs. N.S. indi-
cates p > 0.05.Arthritis Research & Therapy    Vol 8 No 2    Colonna et al.
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ofBALB/c and B6 DCs, in terms of both percentage of positive
cells (Figure 3a,b) and MFI (not shown). In the two control
strains, the expression of costimulatory molecules CD80 and
CD86 shows very consistent percentages in young and adult
mice (CD80: BALB/c 42.12% (young) versus 43.88% (adult);
B6 56.68% (young) versus 52.50% (adult); CD86: BALB/c
34.67% (young) versus 35.46% (adult); B6 38.93% (young)
versus 38.25% (adult)). We found the same consistency in
NZM2410 DCs for CD86 (34.29% (young) versus 36.29%
(adult)), but not for CD80 (44.87% (young) versus 29.78%
(adult)) (compare Figure 2c,d with Figure 3a). Because these
data were collected from a large number of mice, especially in
the adult populations, and in separate experiments over a
period of months, such consistency strengthens the signifi-
cance of the altered expression ratio of CD80 to CD86
observed in adult mice with lupus.
The increase in CD40-positive DCs precedes the onset of 
lupus disease
We also investigated CD40 expression in the same group of
young mice. We found that young NZM2410 mice have a
higher percentage of CD40-positive DCs in their spleens than
either BALB/c or B6 mice. The two control strains had very
similar levels of CD40-positive DCs (Figure 3c), both signifi-
cantly lower than in NZM2410 mice. The percentages of
CD40-positive DCs decreased with age in the three strains,
with a more pronounced effect in B6 mice (compare Figure 2e
with Figure 3c). Although the functional significance of these
age-related differences is worth further investigation, our
results show that DCs from lupus-prone mice express abnor-
mal and long-lasting levels of this fundamental marker.
In summary, we found that DCs from lupus-prone mice show
a pathologic state of activation in comparison with age-
matched control mice. Our analysis suggests that the
decreased CD80/CD86 ratio may be linked to the full devel-
opment of the autoimmune disease, whereas the overexpres-
sion of CD40 pre-dates the occurrence of overt autoimmunity
and may therefore be involved in its pathogenesis.
The increase in CD40 positivity is specific to DCs
To determine whether the overexpression of CD40 was a DC-
specific phenomenon, we analyzed the expression of CD40 in
B cells, the other important population of immune cells that
normally express this marker. As expected, a large percentage
of B cells constitutively expressed high levels of CD40. We
found that NZM2410 mice and age-matched BALB/c mice
had similar percentages of CD40-positive B cells, both in adult
animals (Figure 4a) and in young animals (Figure 4b), whereas
B6 B cells showed overall lower levels of expression, espe-
cially in adult mice.
Because the percentage of CD40-positive B cells in
NZM2410 mice was significantly higher only in comparison
with B6 but not with BALB/c mice, and this single difference
was present only after onset of the disease, we propose that
the overexpression of CD40 in lupus-prone mice is DC spe-
cific.
Analysis of CD40 expression in DC subsets
DCs can be subdivided into subsets, characterized by specific
surface markers and functions [23]. We therefore asked which
DC subset is responsible for the increase in CD40-positive
DCs in lupus-prone mice. In young NZM2410 mice, we
observed overexpression of CD40 largely associated with
myeloid DCs. This subset continued to overexpress CD40
after the onset of the disease (Figure 5a). CD8α+ DCs consti-
tutively expressed high levels of CD40 in all three strains (Fig-
Figure 4
B cells from lupus-prone mice express normal levels of CD40 B cells from lupus-prone mice express normal levels of CD40. Percentages of B cells positive for CD40 from mice 6 to 9 months old (a) and 6 to 8 
weeks old (b) are shown. B cells were gated as B220/CD19-positive and CD11c-negative cells. Results of the Kruskal-Wallis test analyses are 
shown in the graphs (k-w) and the post hoc Mann-Whitney test analyses are shown below the graphs. N.S. indicates p > 0.05.Available online http://arthritis-research.com/content/8/2/R49
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ure 5b). Nevertheless, we observed a slightly but significantly
higher percentage of CD40-positive cells in CD8α+ DCs from
lupus-prone mice than in non-autoimmune mice at a young
age. Such overexpression disappeared after lupus onset (Fig-
ure 5b). The pDCs, which normally present a more immature
phenotype than other subsets, expressed low levels of CD40
in all three strains, with normal percentages of CD40 positivity
in young lupus-prone mice (Figure 5c) and increased percent-
ages after lupus onset, although the increase was not statisti-
cally significant (Figure 5c). Because we found greater
variability in the CD40 expression of pDCs from old mice with
lupus than from the other groups of mice, we take into account
that technical reasons may have hampered the statistical sig-
nificance in this comparison (Kruskal-Wallis p = 0.018, Mann-
Whitney NZM versus BALB/c = 0.064, NZM versus B6 =
0.023). We therefore do not completely exclude the involve-
ment of pDCs in the increased DC expression of CD40 after
the onset of the disease.
This thorough analysis suggests that the increase in CD40-
positive DCs is due mainly to the myeloid DCs and to a smaller
extent, before the onset of the disease, to the CD8α+ DCs,
and after disease onset, to pDCs.
The overexpression of CD40 is not constitutive in resting 
DCs
The increase in the percentage of CD40-positive DCs that we
observed in NZM2410 and in NZB-W/F1 mice could be due
to a pro-inflammatory environment present in lupus-prone mice
even months before the onset of the disease, or to a primary
alteration in the state of activation of DCs.
To discriminate intrinsic DC abnormalities from those induced
by environmental factors, we analyzed CD40 expression in
NZM2410, BALB/c, and B6 BM-DCs, grown in culture with a
protocol that generates resting CD11c+ CD11b+ myeloid-like
DCs [17]. In this artificial environment, DCs are influenced
only by themselves and by the cytokines that are provided to
them in culture (Figure 6a). We found that lupus BM-DCs
expressed levels of CD40 comparable to those of BALB/c and
B6 BM-DCs in terms of both percentage of positivity (Figure
6b,c) and MFI (Figure 6b). We found the same results in BM-
DCs grown from both old (Figure 6a–c) and young mice (data
not shown).
These results suggest that lupus DCs do not have a primary
alteration in their expression of CD40, but that the overexpres-
sion observed ex vivo may be the result of a chronic exposure
or altered response to activators in vivo.
Lupus DCs have a normal capacity to upregulate CD40 
expression after activation
To determine whether lupus DCs have a normal capacity to
upregulate CD40 expression after activation, we used the tra-
ditional protocol by Inaba and colleagues to isolate splenic
DCs [18]. This protocol gives rise to a pure (more than 90%;
data not shown) population of cells double positive for CD11b
and CD11c and negative for CD8α or B220, therefore resem-
bling myeloid DCs. Moreover, DCs are highly activated by the
procedure, with more than 80% of DCs expressing high levels
of costimulatory molecules (not shown). Although the stimulus
that induces DC activation is unclear, this protocol allowed us
to analyze the intrinsic capacity of DCs to upregulate CD40
Figure 5
CD40 expression in three major DC subsets CD40 expression in three major DC subsets. Percentages and standard deviations of CD40-positive cells in myeloid (a), CD8α+ (b), and plasmacy-
toid (c) DC subsets from young (6 to 8 weeks old) and old (6 to 9 months old) mice were calculated from four to nine mice per group. Only results 
by the Mann-Whitney test analyses with p < 0.05 are indicated.Arthritis Research & Therapy    Vol 8 No 2    Colonna et al.
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[18,24]. We found that lupus DCs from both NZM2410 mice
(Figure 6d) and NZB-W/F1 mice (Figure 6e) upregulated
CD40 to the same extent as the non-autoimmune DCs, there-
fore suggesting that the regulation of CD40 expression is not
intrinsically altered.
Discussion
We have examined the ex vivo costimulatory phenotype of
DCs from NZM2410 and NZB-W/F1 lupus-prone mice, com-
pared with DCs from age-matched non-autoimmune mice. We
found that in lupus-prone mice, after the onset of the disease,
DCs expressed an abnormal state of activation with
decreased levels of CD80 and CD54, normal levels of CD86,
and a specific increase in cells expressing CD40. Importantly,
the CD40 increase was already present months before the
onset of the disease. The overexpression of CD40 may be
important in SLE development because CD40 triggering
could be responsible for the inappropriate stimulation of DCs
to live longer, produce an excess of pro-inflammatory
cytokines, and deliver abnormal activation signals to autoreac-
tive T and B cells.
In the pre-disease stage, the increase in CD40 positivity was
mostly present in myeloid DCs and, to a smaller extent, in
CD8α+ DCs. Both DC subsets have been proposed to induce
peripheral tolerance [25] unless they receive an activation sig-
nal, such as CD40 triggering, that induces the production by
DCs of large amounts of pro-inflammatory cytokines and stim-
ulates T cells [26]. Our results therefore suggest that in young
lupus-prone mice, months before the appearance of any
autoantibodies, DCs are prone to escape from a tolerogenic
status.
The small pDC subset has been proposed to be important in
lupus pathogenesis [27] because pDCs can produce large
amounts of type I IFN, which is considered altered in this dis-
ease [5]. CD40 triggering was one of the first stimuli shown to
induce the production of type I IFN by pDCs [28]. Although
Figure 6
Regulation of CD40 expression is not intrinsically altered in lupus DCs Regulation of CD40 expression is not intrinsically altered in lupus DCs. We grew bone marrow-derived dendritic cells (BM-DCs) from NZM2410, 
BALB/c, and B6 mice 6 to 9 months old and stained them at day 6 to 7 of culture. Gating of CD11c+ cells (a) and CD40 expression (b) in resting 
BM-DCs from NZM2410 (thick dark grey line), BALB/c (light grey area), and B6 (thin black line) mice. (c) Percentages of CD40-positive BM-DCs, 
gated as in (a) and considered CD40-positive using the threshold shown in (b) from three experiments, conducted with three independent BM-DCs 
cultures. Error bars show SD. (d,e) Mean fluorescence intensity (MFI) of CD40 expression in splenic myeloid DCs isolated and cultured overnight in 
vitro from NZM2410 (d) and NZB-W/F1 (e) mice 6 to 9 months old.Available online http://arthritis-research.com/content/8/2/R49
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the increase in CD40 expression that we found in pDCs, after
the onset of lupus, did not reach statistical significance with
non-parametric tests, we cannot exclude CD40-CD40L inter-
actions as a mechanism by which pDCs are induced to over-
produce type I IFN and sustain autoimmunity.
We have found that resting lupus BM-DCs, differentiated in
the artificial environment of culture in vitro, did not express
increased levels of CD40. Furthermore, splenic DCs from
mice with lupus showed a normal upregulation of CD40
expression on activation in vitro. These results suggest that
lupus DCs do not have a primary and constitutive alteration in
their regulation of CD40, but they may be induced to overex-
press CD40 by a chronic stimulus.
The decreased CD80/CD86 ratio in DCs from NZM2410
mice after the onset of the disease resembles the defective
costimulatory profile found in DCs from patients with SLE [2,4]
and validates the use of NZM2410 and NZB-W/F1 strains as
murine models for the study of human SLE. CD80 and CD86
are ligands of CD28/CTLA4 and may have different functions
[29]: although both CD80 and CD86 activate effector T cells,
CD80 seems to be especially important for the stimulation of
T regulatory cells and, therefore, the inhibition of the immune
response. Indeed, DNA immunization with plasmids encoding
CD80 induces weaker responses than with plasmids encod-
ing CD86 [30]. In diabetic mice and in lupus-prone MRL/lpr
mice, the blockade of CD80 worsens the severity of both dis-
eases, whereas blockade of CD86 prevents diabetes and has
mild effects on lupus [31,32]. These data suggest the fascinat-
ing hypothesis that the unbalanced expression of CD80 and
CD86 in lupus DCs may impair the capacity of DCs to engage
regulatory T cells, which would lead to the inappropriate stim-
ulation of autoreactive B cells and the maintenance of the
autoimmune disorder.
Recently, Zhu and colleagues [14] reported that DCs from
NZM2410 single-locus derivative B6.Sle3 mice are hyperacti-
vated and hyperstimulate T cells. Some of our results agree
with their data, but some differ. Indeed, they found, as we did,
that DCs from the spleens of mice 9 to 12 months old hyper-
stimulate T cells (data not shown). However, they also demon-
strated increased expression of CD40, CD54, CD80, and
CD86, with a normal CD80/CD86 ratio, whereas we found an
increased expression of CD40 with decreased levels of CD80
and CD54. Although we cannot exclude technical reasons to
explain the dissimilarities, we think that genetic and disease
differences between the two strains of mice can account for
the discrepancies. Indeed, NZM2410 mice develop an overt
form of lupus, with the full repertoire of autoimmune features
and severe glomerulonephritis, whereas B6.Sle3 mice display
some autoimmune features but do not develop glomerulone-
phritis. We therefore propose that NZM2410 mice and their
single-locus derivative B6.Sle3 mice have a genetic abnormal-
ity, still to be determined and not intrinsic to DCs, that induces
upregulation of CD40 in DCs in vivo before and after the onset
of the disease. In NZM2410 mice, the involvement of other
immune abnormalities would lead to a decreased CD80/
CD86 ratio on DCs, and ultimately to severe overt disease,
hypothetically because of impaired activation of regulatory T
cells.
CD40-CD40L interaction has been found to be involved in the
pathogenesis of lupus in four murine models [33-37], and
ectopic expression of CD40L on B cells induces a lupus-like
autoimmune disease [38]. In patients with SLE, T cells overex-
press CD40L for extended periods [39,40], and activated B
cells express CD40L ectopically [41]. Analysis of the literature
suggests that the overexpression of CD40 and CD40L may be
independent phenomena and may both be required for full
lupus development.
Long-term administration of anti-CD40L antibody prevents the
production of high-titer autoantibodies and disease onset in
mice [34,36,42]. In (SWRxNZB)F1 mice, it also prevented DC
accumulation, suggesting that it may be CD40-CD40L
dependent [11]. Our finding of the increase in CD40-express-
ing DCs in lupus-prone mice before the onset of the disease
suggests that CD40 on DCs may have a role in the pathogen-
esis of this autoimmune disease. We therefore propose that
the marked effects of the blockade of CD40L in patients and
murine model of lupus are also due to the inhibition of CD40
triggering on DCs. Because anti-CD40L blockade has raised
safety concerns in patients with SLE [43], we propose that the
inhibition of the expression and function of CD40 in DCs may
be an alternative therapeutic strategy.
Conclusion
Our results suggest that the dendritic cells, pivotal links
between the innate and the adaptive immune system, play an
important role in the pathogenesis of the autoimmune disease
lupus and should be considered as a therapeutic target in SLE
through a specific intervention on the expression of costimula-
tory molecules.
Table 1
Lupus dendritic cells show a decreased CD80/CD86 ratio ex 
vivo
Mouse strain CD80/CD86 p
BALB/c 1.23 ± 0.39
NZM 0.79 ± 0.34 0.006
C57BL/6 1.32 ± 0.35
We calculated CD80/CD86 ratios, dividing the percentage of 
dendritic cells positive for CD80 by the percentage of dendritic cells 
positive for CD86 in each mouse (ex vivo) analyzed. Ratios are 
shown as means ± SD, and the Kruskal-Wallis p value for these 
ratios is shown.Arthritis Research & Therapy    Vol 8 No 2    Colonna et al.
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